Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression

Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards and Duncan I. Jodrell
Yann Wallez
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yann Wallez
  • For correspondence: Yann.Wallez@cruk.cam.ac.uk Fran.Richards@cruk.cam.ac.uk
Charles R. Dunlop
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles R. Dunlop
Timothy Isaac Johnson
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siang-Boon Koh
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
2Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
3Harvard Medical School, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Siang-Boon Koh
Chiara Fornari
4Safety and ADME Translational Sciences Department, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James W.T. Yates
5Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Bernaldo de Quirós Fernández
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Lau
5Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frances M. Richards
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frances M. Richards
  • For correspondence: Yann.Wallez@cruk.cam.ac.uk Fran.Richards@cruk.cam.ac.uk
Duncan I. Jodrell
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-18-0010 Published August 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: June 2018 to January 2021

AbstractFull-text HTMLPDF
Total430724552240

Cited By

Article Information

Volume 17, Issue 8, pp. 1670-1682

DOI 
https://doi.org/10.1158/1535-7163.MCT-18-0010
PubMed 
29891488

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received January 8, 2018
  • Revision received April 16, 2018
  • Accepted May 30, 2018
  • Published first June 11, 2018.

Article Versions

  • Previous version (June 11, 2018 - 05:35).
  • Previous version (July 13, 2018 - 06:41).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2018 American Association for Cancer Research.

Author Information

  1. Yann Wallez1,*,
  2. Charles R. Dunlop1,
  3. Timothy Isaac Johnson1,
  4. Siang-Boon Koh1,2,3,
  5. Chiara Fornari4,
  6. James W.T. Yates5,
  7. Sandra Bernaldo de Quirós Fernández1,
  8. Alan Lau5,
  9. Frances M. Richards1,*, and
  10. Duncan I. Jodrell1
  1. 1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  2. 2Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  3. 3Harvard Medical School, Boston, Massachusetts.
  4. 4Safety and ADME Translational Sciences Department, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  5. 5Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  1. ↵*Corresponding Authors:
    Yann Wallez, University of Cambridge, Cambridge CB2 0RE, United Kingdom. Phone: 01223-769642; E-mail: Yann.Wallez{at}cruk.cam.ac.uk; and Frances M. Richards, Fran.Richards{at}cruk.cam.ac.uk
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 17 (8)
August 2018
Volume 17, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards and Duncan I. Jodrell
Mol Cancer Ther August 1 2018 (17) (8) 1670-1682; DOI: 10.1158/1535-7163.MCT-18-0010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R. Dunlop, Timothy Isaac Johnson, Siang-Boon Koh, Chiara Fornari, James W.T. Yates, Sandra Bernaldo de Quirós Fernández, Alan Lau, Frances M. Richards and Duncan I. Jodrell
Mol Cancer Ther August 1 2018 (17) (8) 1670-1682; DOI: 10.1158/1535-7163.MCT-18-0010
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • eFT226, a Selective Inhibitor of eIF4A-Mediated Translation
  • Peptide Inhibiting Breast Cancer by Disrupting SND1–MTDH
  • TTC-352 Pharmacology and Mechanisms to Treat Breast Cancer
Show more Small Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement